


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. In amendments to the claims, additions are represented by underlining and deletions are represented by ~~striketrough~~ or, in cases of five characters or fewer, by ~~[[double brackets]]~~.

1. (Currently Amended) A method for inhibiting reseeding of cancer cells during or after surgical resection of a tumor ~~anchorage dependent cancer cell proliferation~~: comprising administering a ~~NF-κB inhibitor~~ to a subject within 10 days of the resection, ~~wherein the NF-κB inhibitor causes an NF-κB inhibition and has~~ a compound having the structure




wherein R², R³, and R⁴ are, independently, hydrogen, alkyl, halogenated alkyl, alkenyl, alkynyl, aralkyl, or substituted or ~~unsubstituted~~ unsubstituted aromatic, wherein the compound is the E- or Z-isomer, ~~and wherein the subject has had a tumor resected.~~


- 2-7. (Canceled)
8. (Currently Amended) The method of claim 1, wherein the cancer cells are ~~is an~~ abdominal ~~cancer~~, hepatic ~~cancer~~, peritoneal ~~cancer~~, parietal ~~cancer~~, rectal ~~cancer~~, stomach ~~cancer~~, or colon cancer cells.
9. (Previously Presented) The method of claim 1, wherein the cancer cells utilize NF-κB for mitogenesis.
10. (Previously Presented) The method of claim 1, wherein the cancer cells utilize NF-κB for readhesion.

11. (Currently Amended) The method of claim 1, wherein the cancer ~~cell comprises~~ cells comprise an APC mutation.
12. (Currently Amended) The method of claim 1, wherein the cancer ~~cell does~~ cells do not contain an activating mutation on β -catenin.
13. (Currently Amended) The method of claim 1, wherein the cancer ~~cell expresses~~ cells express the COX2 gene.
14. (Currently Amended) The method of claim 13, wherein the cancer ~~cell overexpresses~~ cells overexpress the COX2 gene.
15. (Currently Amended) The method of claim 1, wherein the cancer ~~cell does~~ cells do not express the COX2 gene.
16. (Canceled)
17. (Canceled)
18. (Previously Presented) The method of claim 1, wherein the cancer cells are colon cancer cells.
19. (Withdrawn) The method of claim 1, wherein the cancer cells are rectal cancer cells.
- 20-25. (Canceled)
26. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B inhibitor~~ compound causes a decrease in the expression of anti-apoptotic proteins.
27. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B inhibitor~~ compound inhibits I κ B NF- κ B phosphorylation.
28. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B inhibitor~~ compound inhibits TNF α induced NF- κ B activation.
- 29-36. (Canceled)

37. (Previously Presented) The method of claim 1, wherein R³ and R⁴ are hydrogen.
38. (Previously Presented) The method of claim 1, wherein R² is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, substituted or unsubstituted phenyl, or benzyl.
39. (Previously Presented) The method of claim 1, wherein R² is a phenyl group having at least one alkyl group.
40. (Previously Presented) The method of claim 1, wherein the compound is the E-isomer.
41. (Withdrawn-Currently Amended) The method of claim 1, wherein the ~~NF-κB inhibitor~~ compound has the structure



42. (Currently Amended) The method of claim 1, wherein the ~~NF-κB inhibitor~~ compound has the structure



43-64. (Canceled)

65. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered prior to the resection.
66. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered after the resection.
67. (Canceled)
68. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered within 5 days of the resection.
69. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered within 1 ~~days~~ day of the resection.
70. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered within 10 hours of the resection.
71. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered within 1 hour of the resection.
72. (Currently Amended) The method of claim 1, wherein the ~~NF- κ B-inhibitor~~ compound is administered within 0.5 hours of the resection.